Observational studyNeurology2022
Prepandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults.
Registry-linked trialOpen access · hybridAbstract readObservational Study
In one paragraph
Observational study in Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02485730 (Cohort Study for Early Identification of Markers in Cognitively Healthy Family Members of Patients With Alzheimer's Disease), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 41% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cohort Study for Early Identification of Markers in Cognitively Healthy Family Members of Patients With Alzheimer's Disease
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Sex differences in Alzheimer's disease: a systematic review of two decades of neuroimaging research.The British journal of radiology · 2026Pooled it
- Psychological resilience trajectories after the COVID-19 pandemic: the role of lifestyle and psychosocial factors in a cohort at increased alzheimer's disease risk.Social psychiatry and psychiatric epidemiology · 2026Article
- Anti-Amyloid Drugs for Alzheimer's Disease: Considering the Role of Depression.Neuro-degenerative diseases · 2025Article
- Inflammatory biomarkers for neurobehavioral dysregulation in former American football players: findings from the DIAGNOSE CTE Research Project.Journal of neuroinflammation · 2024Article
- Sex differences in the relationship between depression and Alzheimer's disease-mechanisms, genetics, and therapeutic opportunities.Frontiers in aging neuroscience · 2024Review
- Links between COVID-19 and Alzheimer's Disease-What Do We Already Know?International journal of environmental research and public health · 2023Review
- Nicotinic acetylcholine receptors and learning and memory deficits in Neuroinflammatory diseases.Frontiers in neuroscience · 2023Review
- Regional amyloid accumulation, post-traumatic distress, and intrusive symptoms in cognitively unimpaired older adults at risk for Alzheimer's.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 2 institutions in 5 countries.
Muge AkinciFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Cleofé Peña-GómezFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Gregory OpertoFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Sherezade Fuentes-JulianFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Carme DeulofeuFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Gonzalo Sánchez-BenavidesFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Marta Milà-AlomàFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Oriol Grau-RiveraFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Nina GramuntFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Arcadi NavarroFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Carolina MinguillónFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Karine FauriaFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Ivonne SuridjanFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Gwendlyn KollmorgenFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Anna BayfieldFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Kaj BlennowFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.ORCID 0000-0002-1890-4193
Henrik ZetterbergFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.ORCID 0000-0002-4671-6763
José Luis MolinuevoFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Marc Suárez-CalvetFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.
Juan Domingo GispertFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain.ORCID 0000-0002-6155-0642
Eider M Arenaza-UrquijoFrom the BarcelonaBeta Brain Research Center (BBRC) (M.A., C.P.-G., G.O., S.F.-J., C.D., G.S.-B., M.M.-A., O.G.-R., A.N., C.M., K.F., J.L.M., M.S.-C., J.D.G., E.M.A.-U.), Pasqual Maragall Foundation, Barcelona; Universitat Pompeu Fabra (M.A., M.M.-A., A.N., J.D.G.), Barcelona; IMIM (Hospital del Mar Medical Research Institute) (G.S.-B., M.M.-A., O.G.-R., C.M., M.S.-C., J.D.G., E.M.A.-U.), Barcelona; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (G.S.-B., O.G.-R., C.M., K.F., M.S.-C., E.M.A.-U.), Madrid; Servei de Neurologia (O.G.-R., M.S.-C.), Hospital del Mar, Barcelona; Fundació Pasqual Maragall (N.G.), Barcelona; Centre for Genomic Regulation (CRG) (A.N.), Barcelona Institute of Science and Technology (BIST); Institute of Evolutionary Biology (UPF-CSIC) (A.N.), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona; Institució Catalana de Recerca i Estudis Avançats (ICREA) (A.N.), Barcelona, Spain; Roche Diagnostics International Ltd (I.S.), Rotkreuz, Switzerland; Roche Diagnostics GmbH (G.K., A.B.), Penzberg, Germany; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.), London; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; H. Lundbeck A/S (J.L.M.), Denmark; and Centro de Investigación Biomédica en Red Bioingeniería (J.D.G.), Biomateriales y Nanomedicina, Madrid, Spain. eiderarenaza@gmail.com.
ALFA Study
Roche (Switzerland) · CHUniversitat Pompeu Fabra · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesIncreased anxious-depressive symptomatology is observed in the preclinical stage of Alzheimer disease (AD), which may accelerate disease progression. We investigated whether β-amyloid, cortical thickness in medial temporal lobe structures, neuroinflammation, and sociodemographic factors were associated with greater anxious-depressive symptoms during the COVID-19 confinement.
methodsThis retrospective observational study included cognitively unimpaired older adults from the Alzheimer's and Families cohort, the majority with a family history of sporadic AD. Participants performed the Hospital Anxiety and Depression Scale (HADS) during the COVID-19 confinement. A subset had available retrospective (on average: 2.4 years before) HADS assessment, amyloid [
resultsWe included 921 (254 with AD biomarkers) participants. β-amyloid positivity (B = 3.73; 95% CI = 1.1 to 6.36; DISCUSSION: Our results link AD-related pathophysiology and neuroinflammation with greater anxious-depressive symptomatology during the COVID-19-related confinement, notably in women. AD pathophysiology may increase neuropsychiatric symptomatology in response to stressors. This association may imply a worse clinical prognosis in people at risk for AD after the pandemic and thus deserves to be considered by clinicians. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier NCT02485730.
Indexed as
Alzheimer DiseaseCOVID-19AgedAmyloid beta-PeptidesAnxietyBiomarkersDepressionFemaleGlial Fibrillary Acidic ProteinHumansInterleukin-6MalePositron-Emission TomographyRetrospective Studiestau ProteinsAmyloid beta-PeptidesBiomarkersGlial Fibrillary Acidic ProteinInterleukin-6tau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT02485730ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.